Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HEPA
DateTimeSourceHeadlineSymbolCompany
20/04/202406:30GlobeNewswire Inc.Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialNASDAQ:HEPAHepion Pharmaceuticals Inc
17/02/202401:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
17/02/202400:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsNASDAQ:HEPAHepion Pharmaceuticals Inc
15/02/202407:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HEPAHepion Pharmaceuticals Inc
04/01/202409:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at NASH-TAG 2024NASDAQ:HEPAHepion Pharmaceuticals Inc
04/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
08/12/202300:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
29/11/202308:15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNASDAQ:HEPAHepion Pharmaceuticals Inc
14/11/202308:05GlobeNewswire Inc.Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNASDAQ:HEPAHepion Pharmaceuticals Inc
11/11/202300:50GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
09/11/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HEPAHepion Pharmaceuticals Inc
25/10/202323:30GlobeNewswire Inc.Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelNASDAQ:HEPAHepion Pharmaceuticals Inc
29/09/202322:00GlobeNewswire Inc.Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/09/202306:05GlobeNewswire Inc.Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202322:00GlobeNewswire Inc.New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramNASDAQ:HEPAHepion Pharmaceuticals Inc
19/09/202323:00GlobeNewswire Inc.Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerNASDAQ:HEPAHepion Pharmaceuticals Inc
18/09/202322:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HEPAHepion Pharmaceuticals Inc
14/09/202322:45GlobeNewswire Inc.Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisNASDAQ:HEPAHepion Pharmaceuticals Inc
07/09/202306:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
07/09/202306:30GlobeNewswire Inc.Hepion Pharmaceuticals Announces Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
25/07/202306:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
22/07/202306:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
22/07/202306:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HEPAHepion Pharmaceuticals Inc
16/06/202306:45GlobeNewswire Inc.Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202322:22GlobeNewswire Inc.Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
25/05/202306:45GlobeNewswire Inc.Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/05/202321:00GlobeNewswire Inc.Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersNASDAQ:HEPAHepion Pharmaceuticals Inc
20/05/202306:05GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
13/05/202306:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HEPAHepion Pharmaceuticals Inc
11/05/202301:15GlobeNewswire Inc.Hepion Pharmaceuticals, Inc. Announces Reverse Stock SplitNASDAQ:HEPAHepion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:HEPA